<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02730624</url>
  </required_header>
  <id_info>
    <org_study_id>PIP-56501141</org_study_id>
    <nct_id>NCT02730624</nct_id>
  </id_info>
  <brief_title>Piperacillin/Tazobactam in Critically Ill Patients With Severe Sepsis and Septic Shock</brief_title>
  <official_title>Population Pharmacokinetics and Pharmacodynamics Study of Piperacillin/Tazobactam During Early Phase in Critically Ill Patients With Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sutep Jaruratanasirikul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is prospective study to assess the pharmacodynamics (t&gt;MIC) of 4.5 g every 6 h of
      piperacillin/tazobactam in patients with early phase of severe sepsis/septic shock following
      administration by a 30 min infusion.

      Clinical and laboratory data such as age, sex, body weight, electrolyte, vital signs, APACHAE
      II score, BUN, Cr and fluid balance will be collected.

      Fifty patients will be enrolled in this study. Piperacillin pharmacokinetic study will be
      carried out during the piperacillin/tazobactam therapy.

      Each patient received 4.5 g every 6 h of piperacillin/tazobactam within 24 h of severe sepsis
      or septic shock, blood samples (approximately 3 ml) will be obtained by direct venipuncture
      at the following time: 0, 0-0.5, 0.5-2, 2-4 and 4-6 h after piperacillin/tazobactam therapy.

      Concentration of piperacillin in plasma will be simulated in Monte Carlo technique to get
      PK/PD index and reported to % PTA and % CFR.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of piperacillin in plasma</measure>
    <time_frame>6 hour after the piperacillin dose</time_frame>
    <description>Concentration of piperacillin in plasma will be simulated in Monte Carlo simulation to assess PK/PD index as 40% and 100% T&gt;MIC and will be reported as %PTA.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Early Phase of Severe Sepsis and Septic Shock</condition>
  <arm_group>
    <arm_group_label>piperacillin/tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin-tazobactam</intervention_name>
    <description>4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h and blood sample were obtained by direct venepuncture at 0, 0-0.5, 0.5-2, 2-4 and 4-6 hour after drug administration</description>
    <arm_group_label>piperacillin/tazobactam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  sepsis patient (defined by 2011 SCCM/ESICM/ACCP/ATS/SIS International sepsis
             definition conference)

          -  severe sepsis or septic sock was defined by

               -  Severe sepsis (sepsis with organ dysfunction)

               -  Septic shock (sepsis with systolic arterial pressure&lt;90 mmHg, mean arterial
                  pressure&lt;60 mmHg or decrease systolic blood pressure&gt; 40 mmHg from base line)

        Exclusion Criteria:

          -  Patients who are pregnant.

          -  Patients who have documented hypersensitivity to beta-lactam

          -  Patients who are dialysis

          -  Patients who are severe sepsis or septic shock more than 24 hour
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Sutep Jaruratanasirikul</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>piperacillin/tazobactam</keyword>
  <keyword>critically ill</keyword>
  <keyword>severe sepsis</keyword>
  <keyword>septic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

